The Cost of Relapse in Schizophrenia

PharmacoEconomics

Volumn 35, Issue 9, 2017, Pages 921-936

  Pennington, Mark ^a   McCrone, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIBLIOGRAPHIC DATABASE; COST EFFECTIVENESS ANALYSIS; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HOSPITAL COST; HUMAN; ICD-9; LENGTH OF STAY; MEDICAL RECORD; MENTAL DETERIORATION; MENTAL HEALTH; MENTAL PATIENT; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; HOSPITALIZATION; PATHOPHYSIOLOGY; RECURRENT DISEASE; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS;

EID: 85019831718     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-017-0515-3     Document Type: Review

References (81)

1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. schizophrenia: manifestations, incidence and course in different cultures A World Health Organization Ten-Country Study. Psychological medicine. Monogr Suppl. 1992;20:1–97.
2. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007;10(1):23.
3. Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, François C. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–71.
4. Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35(1):25–42.
5. Taylor M, Chaudhry I, Cross M, McDonald E, Miller P, Pilowsky L, Strickland P. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharm Clin. 2005;20(3):175–81.
6. Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.
7. Kay SR, Flszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261.
8. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, Thornicroft G, Vazquez-Barquero JL, Knudsen HC, Becker T. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. Acta Psychiat Scand. 2002;105(1):42–54.
9. Heider D, Bernert S, König HH, Matschinger H, Hogh T, Brugha TS, Bebbington PE, Azorin M, Angermeyer MC, Toumi M. Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom—findings from the European schizophrenia Cohort (EuroSC). Eur Psychiatry. 2009;24(4):216–24.
10. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10(1):2.
11. Organisation for Economic Co-operation and Development. Purchasing Power Parities for GDP dataset. 2016. http://stats.oecd.org/Index.aspx?DataSetCode=SNA_Table4#. Accessed Apr 2017.
12. Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy: J Res Debate Pract. 2010;6(1):51–9.
13. Adam T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs. Cost Eff Resour Alloc. 2003;1(1):3.
14. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.
15. Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS. Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics. J Med Econ. 2013;16(11):1290–9.
16. Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012;3(4):e183–94.
17. Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. Adm Policy Ment Health. 2001;28(5):335–51.
18. Kozma C, Muser E, Benson C, Mao L, Starr HL, Alphs L. Health resource and criminal justice system costs for young clinical trial patients with schizophrenia and prior incareration by treatment failure status. Value Health. 2015;18(3):A122.
19. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–51.
20. Zeidler J, Slawik L, Fleischmann J, Greiner W. The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Econ Rev. 2012;2(1):1–8.
21. Kilian R, Matschinger H, Becker T, Angermeyer MC. A longitudinal analysis of the impact of social and clinical characteristics on the costs of schizophrenia treatment. Acta Psychiatr Scand. 2003;107(5):351–60.
22. Daltio CS, Mari JJ, Ferraz MB. Direct medical costs associated with schizophrenia relapses in health care services in the city of São Paulo. Revista de Saúde Pública. 2011;45(1):14–23.
23. Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, Lim BP, Sim K. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. Int Clin Psychopharmacol. 2016;31(2):84–92.
24. Zhai J, Guo X, Chen M, Zhao J, Su Z. An investigation of economic costs of schizophrenia in two areas of China. Int J Ment Health Syst. 2013;7(1):26.
25. Wu J, He X, Liu L, Ye W, Montgomery W, Xue H, McCombs JS. Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s republic of china. Neuropsychiatr Dis Treat. 2015;11:983.
26. Fitzgerald P, de Castella A, Arya D, Simons WR, Eggleston A, Meere S, Kulkarni J. The cost of relapse in schizophrenia and schizoaffective disorder. Australas Psychiatry. 2009;17(4):265–72.
27. Lindström E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65(6):403–13.
28. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (schizophrenia Outpatient Health Outcomes) study. Prog Neuro-Psychophys. 2009;33(5):835–41.
29. Hemels M, Diels J, González B, Jensen R. PMH19 cost of relapse in schizophrenia in Europe: The Constatre Study. Value Health. 2011;14(7):A290.
30. Gandhi R, Figueroa C. Inpatient burden of childhood schizophrenia in the United States. J Am Acad Child Adolesc Psychiatry. 2016;55(10):S236.
31. Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B. Impact of paliperidone palmitate versus oral atypical antipsychotics on health care resource use and costs in veterans with schizophrenia. J Clin Psychiatry. 2016;77(10):e1332.
32. Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ. 2015;18(5):357–65.
33. Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4:212267.
34. Bera R, Offord S, Zubek D, Lau G, Lin J, Baker RA, Karson C. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ. 2013;16(4):522–8.
35. Offord S, Lin J, Mirski D, Wong B. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013;30(3):286–97.
36. Offord S, Lin J, Wong B, Mirski D, Baker RA. Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with medicare coverage. Community Ment Health J. 2013;49(6):625–9.
37. Stensland M, Watson PR, Grazier KL. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatr Serv. 2012;63(7):666–71.
38. Desai P, Lawson K, Barner JC, Rascati KL. PMH29 estimation of direct costs of treating schizophrenia for community-dwelling United States residents. Value Health. 2011;14(3):A190–1.
39. Nicholl D, Akhras KS, Diels J, Schadrack J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin. 2010;26(4):943–55.
40. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173–80.
41. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–29.
42. Ascenção R, Gouveia M, Fiorentino F, Alarcão J, Pascoal J, Costa J, Borges M. Hospitalized patients with schizophrenia in Portugal: clinical characterization and costs. Value Health. 2016;19(7):A527.
43. Zaprutko T, Göder R, Kus K, Rakhman L, Bilobryvka R, Nowakowska E. The cost of inpatient care of schizophrenia and treatment schedules used in German Academic Center: Kiel. Psychiatr Q. 2016;87(4):595–603.
44. Evensen S, Wisløff T, Lystad JU, Bull H, Ueland T, Falkum E. Prevalence, employment rate, and cost of schizophrenia in a high-income welfare society: a population-based study using comprehensive health and welfare registers. Schizophr Bull. 2015;42(2):476–83.
45. Henderson C, Knapp M, Yeeles K, Bremner S, Eldridge S, David AS, O’Connell N, Burns T, Priebe S. Cost-effectiveness of financial incentives to promote adherence to depot antipsychotic medication: economic evaluation of a cluster-randomised controlled trial. PloS One. 2015;10(10):e0138816.
46. Mahlich J, Nishi M, Saito Y. Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan. Clinicoecono Outcomes Res: Clinicoecon Outcomes Res. 2015;7:267–72.
47. Zaprutko T, Nowakowska E, Kus K, Bilobryvka R, Rakhman L, Pogłodziński A. The cost of inpatient care of schizophrenia in the polish and Ukrainian Academic Centers—Poznan and Lviv. Acad Psychiatry. 2015;39(2):165–73.
48. Frey S, Linder R, Juckel G, Stargardt T. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. Eur J Health Econ. 2014;15(2):133–42.
49. Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M, Persson U. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after initiation of risperidone long-acting injection. Schizophr Res Treat. 2012;2012:791468. doi:10.1155/2012/791468.
50. Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844–61.
51. Španiel F, Hrdlicka J, Novák T, Kožený J, Hoeschl C, Mohr P, Motlova LB. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study. J Psychiatr Pract. 2012;18(4):269–80.
52. Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand. Clin Drug Investig. 2010;30(11):777–87.
53. Munro J, Osborne S, Dearden L, Pascoe K, Gauthier A, Price M. Hospital treatment and management in relapse of schizophrenia in the UK: associated costs. Psychiatrist. 2011;35(3):95–100.
54. Spill B, Konoppa S, Kissling W, Maino K, Messer T, Heres S. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010;14(1):53–62.
55. Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585–94.
56. Zeidler J, Slawik L, Fleischmann J, Greiner W. PMH20 impact and costs of hospitalization in schizophrenia. Value Health. 2010;13(7):A449.
57. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007;116(1):36–46.
58. Peiró S, Gómez G, Navarro M, Guadarrama I, Rejas J. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Soc Psychiatry Psychiatr Epidemiol. 2004;39(7):507–13.
59. Spannheimer A, Reitberger U, Clouth J, Lothgren M. Length of hospital stay and associated costs for olanzapine vs. haloperidol in the treatment of schizophrenia relapse in Germany. Eur J Health Econ. 2003;4(2):85–9.
60. Garattini L, Rossi C, Tediosi F, Cornaggia C, Covelli G, Barbui C, Parazzini F. Direct costs of schizophrenia in Italian community psychiatric services. Pharmacoeconomics. 2001;19(12):1217–25.
61. Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of schizophrenia in community psychiatric services in Italy: the GISIES study. Health Policy. 2000;51(1):1–8.
62. Anh NQ, Linh BN, Ha NT, Phanthunane P, Huong NT. Schizophrenia interventions in Vietnam: primary results from a cost-effectiveness study. Glob Public Health. 2015;10(sup1):S21–39.
63. Chen Y, Cheng Y, Shi Q, Yu X, Liu Q, Gu X, Shi J, Montgomery W. Medication use patterns, health-care resource utilization and economic burden for patients with schizophrenia in Beijing, China. Value Health. 2015;18(3):A127.
64. He X, Wu J, Jiang Y, Liu L, Ye W, Xue H, Montgomery W. Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China. BMC Health Serv Res. 2015;15(1):149.
65. Chang HC, Tang CH, Huang ST, McCrone P, Su KP. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751–6.
66. Verduzco W, Escobedo O, Anaya P. PMH30 hospitalization costs for schizophrenia relapses in a public psychiatric institution. Value Health. 2009;12(3):A178.
67. Ayer A, Sariöz F, Kanbur B, Yapici A, Demet SM, Tatar F. PMH27 in patient cost of schizophrenia treatment in Turkey. Value Health. 2009;12(3):A177.
68. Lang HC, Su TP. The cost of schizophrenia treatment in Taiwan. Psychiatr Serv. 2004;55(8):928–30.
69. Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Jensen R, Hemels ME. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden. Nord J Psychiatry. 2014;68(6):416–27.
70. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: treatment and management. National Institute for Health and Care Excellence, National Clinical Guideline number 178. http://www.nice.org.uk/guidance/cg178/evidence/full-guideline-490503565. Accessed Jan 2016.
71. Davies A, Vardeva K, Loze JY, L’Italien GJ, Sennfalt K, Baardewijk MV. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275–85.
72. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry. 2008;7(16):1–2.
73. Beard SM, Maciver F, Clouth J, Rüther E. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ. 2006;7(3):165–72.
74. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics. 2005;23(1):75–89.
75. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Man Care. 1998;4:345–55.
76. Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. Pharmacoeconomics. 1998;13(5):575–88.
77. Li H, Song X, Yu X. PMH8 a review of consequences of relapse in schizophrenia. Value Health. 2012;15(7):A670.
78. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508–16.
79. Centre for Mental Health. Pathways to unlocking secure mental health care. London. 2011. http://www.centreformentalhealth.org.uk/pathways-to-unlocking-secure-mental-health-care. Accessed Jan 2016.
80. Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia. BMC Psychiatry. 2010;10(1):11. doi:10.1186/1471-244X-10-11.
81. Robertson AG, Swanson JW, Van Dorn RA, Swartz MS. Economic grand rounds: treatment participation and medication adherence: effects on criminal justice costs of persons with mental illness. Psychiatr Serv. 2014;65(10):1189–91.